Test Code APOAB Apolipoprotein A1 and B, Serum
Specimen Required
Collection Container/Tube:
Preferred: Serum gel
Acceptable: Red top
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL
Collection Instructions: Centrifuge and aliquot 1 mL of serum.
Useful For
Assessment of cardiovascular risk
Follow-up studies in individuals with basic lipid measures inconsistent with risk factors or clinical presentation
Definitive studies of cardiac risk factors in individuals with significant family histories of coronary artery disease or other increased risk factors
Profile Information
Test ID | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
RBAA1 | Apolipoprotein B/A1 ratio | No | Yes |
APOA1 | Apolipoprotein A1, S | Yes | Yes |
APOLB | Apolipoprotein B, S | Yes | Yes |
Method Name
Automated Turbidimetric Immunoassay
Reporting Name
Apolipoprotein A1 and B, SSpecimen Type
SerumSpecimen Minimum Volume
0.5 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Serum | Refrigerated (preferred) | 8 days | |
Frozen | 60 days | ||
Ambient | 24 hours |
Reject Due To
Gross hemolysis | Reject |
Gross lipemia | OK |
Gross icterus | Reject |
Clinical Information
Apolipoprotein B (ApoB) is the primary protein component of low-density lipoprotein (LDL). Apolipoprotein A1 (ApoA1) is the primary protein component of high-density lipoprotein (HDL). Elevated ApoB and decreased ApoA1 are associated with increased risk of cardiovascular disease. Multiple studies have reported that ApoB and ApoA1 are more strongly associated with cardiovascular disease than the corresponding lipoprotein cholesterol fraction (see APOA1 / Apolipoprotein A1, Serum and APOLB / Apolipoprotein B, Serum).
ApoB is present in all atherogenic lipoproteins including LDL, Lp(a), intermediate-density lipoprotein (IDL), and very low-density lipoprotein (VLDL) remnants. ApoA1 is the nucleating protein around which HDL forms during reverse cholesterol transport. The ApoB:ApoA1 ratio represents the balance between atherogenic and antiatherogenic lipoproteins. Several large prospective studies have shown that the ApoB:ApoA1 ratio performs as well, and often better, than traditional lipids as an indicator of risk.(1-3)
Reference Values
Males
Age |
Apolipoprotein A (mg/dL) |
Apolipoprotein B (mg/dL) |
Apolipoprotein B/A1 ratio |
<24 months |
Not established |
Not established |
Not established |
2-17 years |
Low: <115 Borderline low: 115-120 Acceptable: >120 |
Acceptable: <90 Borderline high: 90-109 High: ≥110 |
<0.8 |
>18 years |
≥120 |
Desirable: <90 Above Desirable: 90-99 Borderline high: 100-119 High: 120-139 Very high: ≥140 |
Lower Risk: <0.7 Average Risk: 0.7-0.9 Higher Risk: >0.9 |
Females
Age |
Apolipoprotein A (mg/dL) |
Apolipoprotein B (mg/dL) |
Apolipoprotein B/A1 ratio |
<24 months |
Not established |
Not established |
Not established |
2-17 years |
Low: <115 Borderline low: 115-120 Acceptable: >120 |
Acceptable: <90 Borderline high: 90-109 High: ≥110 |
<0.8 |
>18 years |
≥140 |
Desirable: <90 Above Desirable: 90-99 Borderline high: 100-119 High: 120-139 Very high: ≥140 |
Lower Risk: <0.6 Average Risk: 0.6-0.8 Higher Risk: >0.8 |
Day(s) Performed
APOA1: Monday through Sunday
APOLB: Monday through Saturday
Report Available
1 to 3 daysPerforming Laboratory
Mayo Clinic Laboratories in RochesterTest Classification
This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.CPT Code Information
82172 x 2
Forms
If not ordering electronically, complete, print, and send a Cardiovascular Test Request Form (T724) with the specimen.